Lamivudine/raltegravir
| Combination of | |
|---|---|
| Lamivudine | Reverse-transcriptase inhibitor |
| Raltegravir | Integrase inhibitor |
| Clinical data | |
| Trade names | Dutrebis |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Lamivudine/raltegravir, sold under the brand name Dutrebis, is a combination medication of lamivudine and raltegravir which is used in the treatment of HIV/AIDS.[1] It is taken by mouth.[1] Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes.[1] It was approved for medical use in the United States in 2015.[1]
References
- ^ a b c d "Dutrebis (lamivudine and raltegravir)" (PDF). FDA. Retrieved 10 December 2017.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |